We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Efficacy and Tolerability of Intravenous Ferric Gluconate in the Treatment of Iron Deficiency Anemia in Patients Without Kidney Disease

Heather J. Miller, MD; James Hu, MD; Johanna K. Valentine, MD; Preston S. Gable, MD
Arch Intern Med. 2007;167(12):1327-1328. doi:10.1001/archinte.167.12.1327.
Text Size: A A A
Published online


Management of iron deficiency anemia requires iron replacement with oral ferrous sulfate or ferrous gluconate. Many patients cannot tolerate or absorb these preparations because of gastrointestinal adverse effects. Iron dextran is approved by the Food and Drug Administration (FDA) for parenteral treatment of iron deficiency anemia and is the drug of choice for treating adults. While iron dextran is generally safe and effective, there are a variety of adverse effects including arthralgias, myalgias, nausea and vomiting, anaphylaxis, and death.1 Intravenous (IV) ferric sodium gluconate (Ferrlecit; Sanofi-Aventis, Dagenham, England) is FDA approved for the treatment of iron deficiency anemia associated with patients with end-stage renal disease who are hemodialysis dependent but is not approved for the treatment of iron deficiency anemia associated with other patient populations. We examined the efficacy and tolerability of this compound in patients without kidney disease treated in outpatient clinics at Naval Medical Center San Diego (NMCSD), San Diego, Calif.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles